日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy

肿瘤和基质细胞中的坏死性凋亡决定了对基于免疫原性细胞死亡的免疫疗法的反应性。

Fernando, Winnie; Clucas, Jarama; Rizzo, Alberto; Singer, Ramsay; Goode, Emily; Tiu, Crescens; Layzell, Scott; Konecnik, Joshua; Wilson, Rebecca; Wicky John, Sidonie; Jouny, Samuel; Guppy, Naomi; Boulat, Victoire; Mannion, Jonathan; Goicoechea, Maria; Tan, Shaun; Lawson, Sam; Starling, Chris; Elshtein, Gabrielle; Ravindran, Nivedita; Montgomery, Anna B; Andres-Ejarque, Rosa; Allen, Mark; Lumbard, Steven; Wallberg, Fredrik; Betteridge, Kai; Scrimgeour, Ross; Robertson, David; Ward, George; Sims, Martin; Smyth, Tomoko; Samson, Andre L; Murphy, James M; Kolarevic Ivankovic, Daniela; Arwert, Esther N; Calado, Dinis P; Grigoriadis, Anita; Smalley, Matthew J; Melcher, Alan; Haider, Syed; Lawrence, Toby; Roxanis, Ioannis; Tutt, Andrew N J; Tenev, Tencho; Meier, Pascal

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma

拮抗凋亡抑制蛋白揭示了一种基于免疫反应的新型T细胞淋巴瘤治疗方法。

Ferrari, Nicola; Ward, George; Gewinner, Christina; Davis, Matthew P; Jueliger, Simone; Saini, Harpreet; Munck, Joanne; Smyth, Tomoko; Ferraldeschi, Roberta; Keer, Harold; Lyons, John; Sims, Martin J

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors

HSP90抑制剂onalespib联合泛CDK抑制剂AT7519治疗晚期实体瘤患者的I期研究

Do, Khanh T; O'Sullivan Coyne, Geraldine; Hays, John L; Supko, Jeffrey G; Liu, Stephen V; Beebe, Kristin; Neckers, Len; Trepel, Jane B; Lee, Min-Jung; Smyth, Tomoko; Gannon, Courtney; Hedglin, Jennifer; Muzikansky, Alona; Campos, Susana; Lyons, John; Ivy, Percy; Doroshow, James H; Chen, Alice P; Shapiro, Geoffrey I

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

在非小细胞肺癌中,酪氨酸激酶抑制剂耐药性的出现可通过一线联合使用 HSP90 抑制剂奥纳莱斯皮来延缓。

Courtin, Aurelie; Smyth, Tomoko; Hearn, Keisha; Saini, Harpreet K; Thompson, Neil T; Lyons, John F; Wallis, Nicola G

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models

HSP90抑制剂AT13387对伊马替尼敏感和耐药的胃肠道间质瘤模型均有效。

Smyth, Tomoko; Van Looy, Thomas; Curry, Jayne E; Rodriguez-Lopez, Ana M; Wozniak, Agnieszka; Zhu, Meijun; Donsky, Rachel; Morgan, Jennifer G; Mayeda, Mark; Fletcher, Jonathan A; Schöffski, Patrick; Lyons, John; Thompson, Neil T; Wallis, Nicola G

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

热休克蛋白 90 抑制剂 AT13387 在体外和体内对非小细胞肺癌均表现出较长的作用时间

Graham Brent, Curry Jayne, Smyth Tomoko, Fazal Lynsey, Feltell Ruth, Harada Isobel, Coyle Joe, Williams Brian, Reule Matthias, Angove Hayley, Cross David M, Lyons John, Wallis Nicola G, Thompson Neil T

Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa

阐明脂质IVa信号传导所需的MD-2/TLR4界面

Walsh, Catherine; Gangloff, Monique; Monie, Tom; Smyth, Tomoko; Wei, Bin; McKinley, Trevelyan J; Maskell, Duncan; Gay, Nicholas; Bryant, Clare